VICO — Vicore Pharma Holding AB Income Statement
0.000.00%
Last trade - 00:00
- SEK1.82bn
- SEK1.34bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 94 | 150 | 295 | 291 | 322 |
Operating Profit | -94 | -150 | -295 | -291 | -322 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -93.3 | -147 | -297 | -289 | -311 |
Provision for Income Taxes | |||||
Net Income After Taxes | -93.1 | -147 | -296 | -288 | -311 |
Net Income Before Extraordinary Items | |||||
Net Income | -93.1 | -147 | -296 | -288 | -311 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -93.1 | -147 | -296 | -288 | -311 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.16 | -2.71 | -4.25 | -3.99 | -2.8 |
Dividends per Share |